Martha Morrell Sells 78,334 Shares of NeuroPace, Inc. (NASDAQ:NPCE) Stock

NeuroPace, Inc. (NASDAQ:NPCE) insider Martha Morrell sold 78,334 shares of the firm’s stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $13.72, for a total transaction of $1,074,742.48. Following the completion of the sale, the insider now owns 81,993 shares of the company’s stock, valued at $1,124,943.96. This trade represents a 48.86 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Martha Morrell also recently made the following trade(s):

• On Wednesday, January 29th, Martha Morrell sold 100 shares of NeuroPace stock. The stock was sold at an average price of $15.00, for a total value of $1,500.00.
• On Friday, January 24th, Martha Morrell sold 3,200 shares of NeuroPace stock. The shares were sold at an average price of $15.01, for a total transaction of $48,032.00.

NeuroPace Price Performance

Shares of NASDAQ:NPCE opened at $13.48 on Thursday. The company has a market cap of $402.35 million, a P/E ratio of -13.48 and a beta of 2.05. The business has a fifty day simple moving average of $12.63 and a 200-day simple moving average of $9.58. NeuroPace, Inc. has a 52 week low of $5.45 and a 52 week high of $17.37. The company has a quick ratio of 4.77, a current ratio of 5.59 and a debt-to-equity ratio of 6.03.

Institutional Trading of NeuroPace

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Two Sigma Advisers LP purchased a new position in shares of NeuroPace during the 4th quarter worth about $117,000. Two Sigma Investments LP acquired a new position in NeuroPace during the fourth quarter worth approximately $293,000. Point72 Asset Management L.P. purchased a new position in NeuroPace during the fourth quarter worth approximately $369,000. Jacobs Levy Equity Management Inc. acquired a new position in shares of NeuroPace in the 4th quarter valued at $639,000. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of NeuroPace in the 4th quarter valued at $112,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on NPCE. JPMorgan Chase & Co. raised their price objective on shares of NeuroPace from $9.00 to $14.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 17th. Wells Fargo & Company raised their price target on NeuroPace from $13.00 to $17.00 and gave the stock an “overweight” rating in a research report on Thursday, January 30th. Finally, UBS Group started coverage on NeuroPace in a research report on Tuesday, January 21st. They issued a “buy” rating and a $17.00 price objective on the stock. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, NeuroPace has a consensus rating of “Moderate Buy” and a consensus target price of $14.80.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.